|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:auditedBy
|
gptkb:Ernst_&_Young
|
|
gptkbp:CEO
|
gptkb:Daniel_O’Day
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:CUSIP
|
375558103
|
|
gptkbp:dividendPaying
|
yes
|
|
gptkbp:fiscalYear
|
December 31
|
|
gptkbp:foundedYear
|
1987
|
|
gptkbp:founder
|
gptkb:Michael_L._Riordan
|
|
gptkbp:hasCompany
|
gptkb:Gilead_Sciences,_Inc.
|
|
gptkbp:headquartersLocation
|
gptkb:Foster_City,_California,_United_States
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:ISIN
|
US3755581036
|
|
gptkbp:legalForm
|
gptkb:public_company
|
|
gptkbp:logo
|
Gilead Sciences logo.svg
|
|
gptkbp:marketCap
|
large cap
|
|
gptkbp:notable_drug
|
gptkb:Biktarvy
gptkb:Harvoni
gptkb:Truvada
gptkb:Veklury
|
|
gptkbp:notableAcquisition
|
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Pharmasset
|
|
gptkbp:notableInvention
|
gptkb:sofosbuvir
tenofovir
|
|
gptkbp:numberOfEmployees
|
2023
~17,000
|
|
gptkbp:products
|
gptkb:remdesivir
antiviral drugs
HIV treatments
hepatitis C treatments
|
|
gptkbp:S&P500Component
|
yes
|
|
gptkbp:sector
|
healthcare
|
|
gptkbp:SIC
|
2836
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
gptkb:NASDAQ-100
gptkb:S&P_500
gptkb:Russell_1000
gptkb:stock_market_index
|
|
gptkbp:stockSymbol
|
gptkb:USD
gptkb:GILD
|
|
gptkbp:subsidiary
|
gptkb:Immunomedics
gptkb:Kite_Pharma
gptkb:Pharmasset
|
|
gptkbp:tradedOn
|
gptkb:NASDAQ:GILD
|
|
gptkbp:website
|
https://www.gilead.com/
|
|
gptkbp:主要业务
|
pharmaceuticals
|
|
gptkbp:bfsParent
|
gptkb:Gilead
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
NASDAQ:GILD
|